Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 3/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 5/20 | 0.38 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.37 |
| ▸ | RORA | P35398 | 1/20 | 0.36 |
| ▸ | RORB | Q92753 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31301344 | 0.94 | SCN2A (0.42) | SCN2ASCN10APDE10ATRPV3GPBAR1 | |
| SCHEMBL31301655 | 0.89 | SCN10A (0.43) | SCN2ASCN10ARORCGPBAR1RORA | |
| SCHEMBL31301398 | 0.86 | SCN10A (0.50) | SCN2ASCN10AGPBAR1 | |
| SCHEMBL31301288 | 0.82 | SCN10A (0.45) | SCN2ASCN10AGPBAR1 | |
| SCHEMBL31301372 | 0.82 | GPBAR1 (0.43) | SCN2ASCN10AGPBAR1 | |
| SCHEMBL31301566 | 0.80 | SCN10A (0.52) | SCN2ASCN10ATRPV3MEN1KMT2A | |
| SCHEMBL31301594 | 0.79 | SCN10A (0.52) | SCN2ASCN10AGPBAR1 | |
| SCHEMBL31301342 | 0.79 | MEN1 (0.43) | SCN2ASCN10AGPBAR1MEN1KMT2A | |
| SCHEMBL31301626 | 0.75 | SCN10A (0.39) | SCN2ASCN10ATRPV3GPBAR1 | |
| SCHEMBL31301335 | 0.74 | SCN10A (0.44) | SCN2ASCN10AGPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727549-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | University of Georgia Research Foundation, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIV GEORGIA (US) | 2026-04-09 | — | — | US | disclosed |
| WO-2024258900-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | SUB1, PFN1, HCCS | SCN2A 2686/4885SCN10A 3171/4885PDE10A 3169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.